Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Press Conference, 2025

By Inderes10/23/2025, 8:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:00

Please go ahead.

Nicklas Westerholm
00:04 - 05:24

Welcome to the Egetis Therapeutics webcast. My name is Nicklas Westerholm, CEO of Egetis Therapeutics. Joining me today are Christian Sonesson, Vice President of Product Strategy and Development, Yilmaz Mahshid, Chief Financial Officer, as well as Karl Hård, Head of Investor Relations. This morning, we issued a press release announcing that Egetis Therapeutics has been granted a rolling new drug application, a so-called NDA review by the US FDA for Emcitate® for the treatment of MCT8 deficiency based on currently available clinical data. This is great news and the result of a very successful pre-NDA meeting we had with the FDA earlier this week. Following the granting of the Breakthrough Therapy designation in July. We are strongly encouraged by the dialogue with the FDA on Emcitate, and we appreciate the agency's collaborative spirit as we work to deliver the first therapy to patients with MCT8 deficiency as efficiently as possible in the US. The objective of the Pre-NDA meeting was to seek FDA advice and agreement on the overall content to support our NDA submission for Emcitate, with a special focus and emphasis on the clinical data package. We have now reached an agreement with the FDA that we can commence a rolling NDA submission in December 2025, targeting a complete NDA submission in early 2026 and the completion of the FDA review process in the third quarter of 2026, as we expect a priority review. This is, of course, a substantial step towards approval in the United States. The Breakthrough Therapy designation was granted in July this year, based on the FDA's review of our independent analysis of the survival data from the international cohort study conducted by the Erasmus Medical Center, which we call the EMC Survival Study. We will start the rolling submission in December with the non-clinical and quality modules of the NDA dossier, and complete the NDA with a clinical module in early 2026. Importantly, the NDA for Emcitate® for the treatment of MCT8 deficiency will be based on currently available clinical data. Considering that MCT8 deficiency is an ultra-rare disease, we have an unusually large and robust clinical data set from six different sources. This includes Triac Trial I with 46 patients, Triac Trial II with 22 patients, where data in the NDA will include long-term safety data up to four years of treatment in younger children. The ReTRIACt study involved 15 patients, the EMC Cohort Study included 67 patients, and the EMC Survival Study comprised over 600 patients, as well as the US Expanded Access Program, where we currently have around 30 patients. Importantly, the ongoing ReTRIACt study is no longer considered pivotal for the new drug application, which it was when the study was originally designed. The study will be closed as soon as possible, and no further patients will be added. The FDA has recommended that the statistical analysis plan be revised. The so-called SAP for the trial will be revised. While I can't comment on any specific details about the ReTRIACt study or the SAP. What I can say is the revised SAP will reflect the fact that the ReTRIACt study is now a complementary study to the survival data and other clinical components in the NDA, rather than being the pivotal study. We estimate top-line results from the ReTRIACt study will be communicated during the fourth quarter of 2025. Data accrued to date will be included in the NDA. So in summary, we are very pleased with the agreement with the FDA, which provides a clear path to an NDA for Emcitate in the US, based on the currently available clinical data within the coming months. So with that, I would like to open up for questions. Operator. Please go ahead.

Operator
05:26 - 05:39

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. The next question comes from Chiara Monteroni from Van Lanschot Kempen. Please go ahead.

Chiara Monteroni
05:46 - 06:09

Hello, Tim. Congratulations on the update and thanks for taking my question. So, as Emcitate oversight has transitioned in the past from the trade division to the endocrinology division, Can you share your thoughts on how this is affecting the regulatory process? Do you believe that this new division facilitated the possibility of a rolling submission?

Nicklas Westerholm
06:11 - 07:29

The next question comes from Chiara Monteroni from Van Lanschot Kempen. Of course. And good morning, Chiara. Good to speak to you again. Now, I think it's a valid question, and as you pointed out, previously our application or IND was situated with the rare disease division. As I mentioned during my initial opening remarks, the dialogue with the FDA has been very open and positive, and we are strongly encouraged by the agency's collaborative spirit. And I think there is a strong appreciation from the agency and the Division of Endocrinology that the unmet medical need for patients with MCT8 deficiency is high, that we have generated an unusually large and robust clinical data set to date, and an appreciation of the disease itself being an ultra-orphan condition. So overall for us, that has been very positive, which was reflected in, I would say, the outcome of the Pre-NDA meeting we held earlier this week.

Chiara Monteroni
07:31 - 07:50

Yes. Really clear. And if I may, I have another question I actually wanted to ask about. Powering. But I will ask it another time. So when are we going to be able to see the survival study published by Erasmus? I know it's in their hands, but I was wondering if maybe you have some timelines.

Nicklas Westerholm
07:51 - 08:20

That's also a very good question. Rightly pointed out, it's not in our hands. The publication and manuscript related to the survival study carried out by EMC, based on data from the international consortium, will be published in the not too distant future. I don't have the insights and I can't comment any further than that, but hopefully in the not too distant future.

Chiara Monteroni
08:21 - 08:23

The next question comes from Chiara Monteroni from Van Lanschot Kempen. Thank you so much.

Nicklas Westerholm
08:24 - 08:25

Thank you, Chiara.

Operator
08:27 - 08:31

The next question comes from Oscar Lamb from Stifel. Please go ahead.

Oscar Lamb
08:33 - 08:51

Hi, Sema, congrats. First of all, regarding the positive updates. I was just wondering, in your discussions with the FDA, have you already discussed the potential label for Emcitate®? And, in particular, if the survival data will end up in the label, which obviously would be important from a pricing perspective.

Nicklas Westerholm
08:52 - 09:39

Sure. And that's a really good question. Thank you, Oscar. And of course, we have had initial discussions around the potential label, as you always do. However, as standard practice, when you are in the process, for example. Leading up to an NDA submission and subsequently a review. This will be discussed in more detail during the review process. From a company perspective, the ambition is, of course, to have as broad a label as possible, including all the possible claims based on the clinical data we have generated to date, including survival benefits.

Oscar Lamb
09:42 - 09:43

Okay. Got it. Thank you.

Nicklas Westerholm
09:43 - 09:44

Thank you.

Operator
09:48 - 09:54

There are no more questions at this time, so I hand the conference back to the speakers for written questions and closing comments.

Karl Hård
09:55 - 10:09

So we have some written questions. And the first one comes from Frederick Tower. And the question is, given that the ReTRIACt study is considered complementary, does it mean that the statistical results are a bit more flexible?

Nicklas Westerholm
10:11 - 10:39

Well, I can't comment in detail. Frederick, thank you for your written question. As mentioned in my opening remarks, while I can't comment on any specific details about the ReTRIACt study or the SAP, what I can say is the revised SAP will reflect the fact that the ReTRIACt study is now considered to be complementary to the survival data and other clinical components in the NDA, rather than a pivotal study.

Karl Hård
10:42 - 12:12

And then there is a follow-up question from Frederick Tower. You mentioned that there is a collaborative spirit at the FDA regarding the priority review voucher program and its potential end. How much does this impact the FDA's plans to make a decision before the end of September? And this is Karl Hård. I can comment on this. I mean, at the moment, the sunset clause for the PRV program is, as you said, the end of September 2026. We know from before that the FDA is forthcoming in trying to be helpful. However, it's also important to note that there is a bill in the House, number H.R. 1262, which is called Give Kids a Chance, has passed the first committee with a vote of 47 to zero to be pushed forward for a vote in the whole House. It currently has over 310 co-sponsors from both Republicans and Democrats. So, that looks very promising that it will also be going forward. If that becomes law, then it would mean that the program would be prolonged until the end of September 2029. But that still needs to happen then.

Nicklas Westerholm
12:18 - 12:55

Thank you so much, Karl, for that update. And with that, we'd like to take the opportunity to thank the participants joining the call today. In summary, we are incredibly pleased with the discussions and the agreement with the FDA, and with the clear path forward to an NDA for Emcitate® in the US, based on the currently available clinical data already in the coming couple of months. We look forward to keeping the market updated as we progress. Thank you very much, and I wish you all a good day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…